Campbell John P, Heaney Jennifer L J, Pandya Sankalp, Afzal Zaheer, Kaiser Martin, Owen Roger, Child J Anthony, Gregory Walter, Morgan Gareth J, Jackson Graham H, Bunce Chris M, Drayson Mark T
Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham B15 2TT, UK.
Department for Health, University of Bath, Bath BA2 7AY, UK.
Br J Cancer. 2017 Sep 5;117(6):835-839. doi: 10.1038/bjc.2017.229. Epub 2017 Jul 20.
Myeloma is consistently preceded by premalignant monoclonal gammopathy of undetermined significance (MGUS). In >5% of MGUS patients there is a second MGUS clone (biclonal gammopathy of undetermined significance; BGUS), yet, at myeloma diagnosis, presentation of biclonal gammopathy myeloma (BGMy) is considered less frequent, implying that myeloma eradicates coexisting MGUS.
In the largest study of its kind, we assessed BGMy frequency amongst 6399 newly diagnosed myeloma patients enrolled in recent UK clinical trials.
Compared to expected prevalence (i.e., >5% of MGUS have BGUS), only 58 of 6399 (0.91%) newly diagnosed myeloma patients had BGMy, indicating myeloma typically eliminates coexistent MGUS. In these 58 BGMy cases, the MGUS plasma cell clone was greatly suppressed in size compared to typical levels observed in conventional MGUS; contrarily, the MGUS clone did not inhibit the myeloma plasma cell clone in BGMy.
Myeloma eliminates the majority of competing MGUS, and when it does not, the MGUS clone is substantially reduced in size.
骨髓瘤之前通常存在意义未明的癌前单克隆丙种球蛋白病(MGUS)。在超过5%的MGUS患者中存在第二个MGUS克隆(意义未明的双克隆丙种球蛋白病;BGUS),然而,在骨髓瘤诊断时,双克隆丙种球蛋白病骨髓瘤(BGMy)的表现被认为较为少见,这意味着骨髓瘤消除了共存的MGUS。
在同类最大规模的研究中,我们评估了参与近期英国临床试验的6399例新诊断骨髓瘤患者中BGMy的发生率。
与预期患病率(即超过5%的MGUS有BGUS)相比,6399例新诊断骨髓瘤患者中只有58例(0.91%)患有BGMy,这表明骨髓瘤通常会消除共存的MGUS。在这58例BGMy病例中,与传统MGUS中观察到的典型水平相比,MGUS浆细胞克隆的大小被极大地抑制;相反,在BGMy中MGUS克隆并未抑制骨髓瘤浆细胞克隆。
骨髓瘤消除了大多数相互竞争的MGUS,而当它不能消除时,MGUS克隆的大小会大幅减小。